WALTHAM,
Mass., Jan. 30, 2025 /PRNewswire/ -- Syndax
Pharmaceuticals (Nasdaq: SNDX), a commercial-stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of
Syndax, as well as members of the Syndax management team, will
participate in the following upcoming investor conferences:
- Guggenheim SMID Cap Biotech Conference in
New York, NY with a fireside chat
on Thursday, February 6, 2025, at
10:30 a.m. ET
- Citi's 2025 Virtual Oncology Leadership Summit with a
fireside chat on Wednesday, February 19,
2025, at 9:00 a.m. ET
A live webcast of the fireside chats will be available in the
Investor section of the Company's website at www.syndax.com, where
a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies. Highlights of the Company's pipeline include
Revuforj® (revumenib), an FDA-approved menin inhibitor,
and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal
antibody that blocks the colony stimulating factor 1 (CSF-1)
receptor. Fueled by our commitment to reimagining cancer care,
Syndax is working to unlock the full potential of its pipeline and
is conducting several clinical trials across the continuum of
treatment. For more information, please visit www.syndax.com/ or
follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-announces-participation-in-february-investor-conferences-302363686.html
SOURCE Syndax Pharmaceuticals, Inc.
